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Abstract
Although many influenza-related deaths are attributable to secondary bacterial infection
with S. pneumoniae, vaccines that simultaneously protect against influenza and pneumo-
coccal infection are currently not developed. The aim of our study was to evaluate the possi-
bility to prevent post-influenza pneumococcal infection using an associated vaccine based
on live influenza vaccine (LAIV) combined with recombinant polypeptides derived from
superficial factors of Group B streptococcus (GBS) determining pathogenicity. We demon-
strated in a model of post-influenza pneumococcal pneumonia that intranasal pneumococ-
cal super-infection seriously complicated the course of A/Shanghai/2/2013(H7N9) CDC-RG
virus infection in mice. Associated immunization using LAIV and GBS vaccine (GBSV) pre-
vented post-influenza pneumococcal pneumonia better than mono-LAIV or GBSV immuni-
zation. At the same time, parenteral pneumococcal post-influenza infection of immune mice
was more severe in the groups immunized using recombinant GBS peptides which can be
explained by antibody-dependent enhancement of infection. In this case, the introduction of
blockers of histamine receptors type 1 and 2 reduced the burden of secondary pneumococ-
cal infection.
Introduction
Many influenza-related deaths are attributable to secondary bacterial infection with S. pneu-
moniae, the most common cause of community-acquired pneumonia [1]. Since 2007, the
pneumococcal serotypes not included in vaccines, begin to dominate and cause disease requir-
ing the use of higher-valent vaccines [2, 3]. In addition, uncontrolled antibiotics consumption
leads to the formation of resistant strains complicating the course of infection [4]. Polysaccha-
ride components of pneumococcal vaccines do not provide long-term immunological
PLOS ONE | https://doi.org/10.1371/journal.pone.0218544 June 25, 2019 1 / 14
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: Desheva Y, Leontieva G, Kramskaya T,
Grabovskaya KB, Karev V, Mamontov A, et al.
(2019) Mucosal vaccine based on attenuated
influenza virus and the group B Streptococcus
recombinant peptides protected mice from
influenza and S. pneumoniae infections. PLoS ONE
14(6): e0218544. https://doi.org/10.1371/journal.
pone.0218544
Editor: Victor C. Huber, University of South Dakota,
UNITED STATES
Received: January 25, 2019
Accepted: June 4, 2019
Published: June 25, 2019
Copyright: © 2019 Desheva et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the manuscript and its Supporting
Information files.
Funding: The authors received no specific funding
for this work.
Competing interests: The authors have declared
that no competing interests exist.
memory, which requires their modification with adjuvants (Prevnar) or constant revaccina-
tion (Pneumo23).
In addition, capsular polysaccharide pneumococcal vaccine only partially protect against
bacterial complications of influenza infection [5]. At the same time, influenza infection quite
often leads to activation of conditionally pathogenic bacteria in the respiratory tract after influ-
enza infection. S. pneumoniae invades its host by colonizing the naso-pharynx asymptomati-
cally as it has been found to be part of the commensal microbiota of the upper respiratory tract
[6, 7]. Influenza infection causes emergence of bacterial complications, mainly bronchitis and
pneumonia, and leads to exacerbation of concomitant chronic diseases [8, 9]. The most well-
known example is the common lethal synergy between influenza virus and pneumococcal or
staphylococcal bacterial secondary infections [10].
Therefore, the aim of our study was to evaluate the possibility of preventing post-influenza
pneumococcal infection by combining live influenza vaccine (LAIV) and recombinant poly-
peptides based on superficial factors of bacteria pathogenicity. In our previous research, it has
been shown that the associated vaccine based on LAIV and recombinant group B streptococ-
cus (GBS) polypeptides protects mice against post-influenza pneumonia following intranasal
infection with GBS after homologous and heterologous influenza infection [11]. Here we eval-
uate potential of such an associated vaccine in preventing pneumococcal post-influenza infec-
tions in mice.
Methods
Viruses and vaccine preparations
The reassortant A/17/Mallard/Netherlands/00/95 (H7N3) was provided from Institute of
Experimental Medicine collection of viruses. The A/Shanghai/2/2013(H7N9) CDC-RG virus
was provided by Centers for the Diseases Control and prevention, USA. The viruses were
propagated in CE and stored at -70˚C. GBS recombinant polypeptides P6 (30-kDa), ScaAB
(35-kDa) were expressed in E.coli and purified as described earlier [12].
Pneumococci cultivation
S. pneumoniae clinical isolates№ 73, serotype 3 or№ 442, serotype 19F were used in this
study were obtained from the collection of the Research Institute of Pediatric Infections
(St. Petersburg, Russia). Pneumococci were cultured in anaerobic conditions at 37˚C for 18
hours in THB medium with 20% horse serum (Becton Dickinson, New Jersey, USA). The
Schaedler agar with sheep red blood cells was used as a solid medium for cultivation and
counting of the bacterial number.
Immunization of mice
The 8 to-10-week-old female DBA/2 mice were acquired from the laboratory breeding nursery
of the Russian Academy of Sciences (Rappolovo, Leningrad Region, Russia). Groups of mice
(60 animals in group) were lightly anesthetized with ether and intranasally (i.n.) vaccinated
with 50 μL divided equally per nostril using the following preparations: 1) live influenza vac-
cine (LAIV) containing 1x107 50% egg infectious dose (EID50) of the A/H7N3 vaccine virus; 2)
GBS vaccine (GBSV) containing the mix of P6 and ScaAB recombinant polypeptides (10 μg
each, 20 μg total); 3) mixed LAIV+GBSV vaccine including 1x107 EID50 of A/17/Mallard/
Netherlands/00/95 (H7N3) virus and GBSV; 4) control animals were inoculated by PBS. The
mice were immunized twice at an interval of 21 days. Three weeks after vaccination and revac-
cination, sera were collected from ether anesthetized mice via submandibular plexus. Nasal
Associated vaccine against post-influenza pneumococcal infections
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secrets were collected from mice after intraperitoneally administration of 0.1 mL of a 0.5%
pilocarpine solution (Sigma-Aldrich, St. Louis, MO, USA) into the tubes containing 0.001 of
serine protease inhibitor phenylmethylsulfonyl fluoride (PMSF). Sera and nasal samples were
stored at -20˚C.
Ethics statement
All procedures involving animals were performed according to the “Rules Laboratory Practice"
Ministry of Health of the Russian Federation№ 708 n. The study was approved by the Local
Ethics Committee for Animal Care and Use at the Institute of Experimental Medicine, Saint-
Petersburg, Russia. Non-terminal procedures were performed under ether anesthesia. Animals
were euthanized by ether inhalation, and all efforts were made to minimize suffering of the
animals. The body weight of the challenged mice was monitored and recorded once a day for
10 days post infection, and mice were euthanized if they lost more than 25% of starting body
weight.
Immunogenicity
Blood samples were taken from the submandibular vein. For hemagglutination-inhibition
assay (HI) sera were treated with receptor-destroying enzyme (RDE, Denka Seiken, Tokyo,
Japan) and tested for HI antibodies against A/17/Mallard/Netherlands/00/95 (H7N3) virus
and against A/Shanghai/2/2013(H7N9) CDC-RG influenza as previously described [13]. The
enzyme-linked immunosorbent assay (ELISA) was conducted to determine serum IgG and
nasal IgA antibodies in 96-well micropltes (Sarstedt AG & Co, Nu¨mbrecht, Germany) as previ-
ously described [13]. For absorption we used 20 HAU/0.1 ml of the whole purified A/H7N3
virus or 20 HAU/0.1 ml of the whole purified A/Shanghai/2/2013(H7N9) CDC-RG virus or
0.2 mg/0.1 ml of GBSV individual components. The end-point ELISA titers were expressed as
the highest dilution that yielded an optical density at 450 nm (OD450) greater than the mean
OD450 plus 3 standard deviations (SD) of negative control wells.
Interaction of immune sera with S. pneumonia
The dot -blot assay was performed using nitrocellulose membranes. Daily cultures of S. pneu-
moniae were washed in PBS and three microliters of each bacterial suspension were applied to
nitrocellulose membranes and dried. The membrane was incubated in blocking buffer (5% dry
milk dissolved in PBS pH 7.4). After the incubation, membrane was treated with mice sera
diluted 1000 times in blocking buffer. Membrane was placed in a conjugate solution (anti-
mouse IgG (Fc-specific)-peroxidase). Color was developed in ready to use TMB Liquid Sub-
strate System for Membranes (Sigma-Aldrich, St. Louis, MO, USA) for 3–5 minutes.
For ELISA-test, the pneumococci of serotype 19F were absorbed on the surface of 96-well
panels for serological reactions (Nalge Nunc International Corporation, Roskilde, Denmark)
overnight. ELISA was performed as described above.
Study of the protective efficacy of combined vaccination against secondary
pneumococcal super-infection
On day 21 after revaccination the mice from all groups were inoculated intranasally with 300
fifty percent mouse infectious doses (MID50) of A/Shanghai/2/2013(H7N9) CDC-RG influ-
enza virus. On 24 hours after viral infection the mice were intranasally inoculated with 50 ml
of PBS containing 2.5x106 CFU of S. pneumonia 3 serotype.
Associated vaccine against post-influenza pneumococcal infections
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Measurement of the viral titer and bacterial colonization in the lungs
To determine the viral titer in the lungs, the samples were collected from mice at 72 h after
viral infection, homogenized in PBS containing 100 U/ml penicillin, 100 μg/ml streptomycin
and centrifuged for 10 min at 6000 g. The viral titers were calculated as log10 of the fifty per-
cent embryonic infectious doses (EID50) using hemagglutination as the endpoint, as described
previously [14].
For measurement of bacterial numbers, lungs were removed from mice at 48 h after bacte-
rial infection and homogenized in PBS using a Retsch MM-400 ball vibratory mill. Serial
10-fold dilutions of homogenates were made in PBS and aliquots of the dilutions were plated
on dense nutrient medium (the Schaedler agar). Plates were incubated at 37˚C in 5% CO2 for
14–16 hours before the colonies were counted under a microscope. The bacterial burden in
colony forming units (CFU) per organ was calculated and expressed as a log 10.
Histopathology
Lung sections obtained at 72 hours after primary viral infection or after 48 hours after pneu-
mococcal invasion were fixed in 10% neutral buffered formalin and embedded in paraffin. Sec-
tions were stained with hematoxylin and eosin.
Mouse model of systemic S. pneumoniae super- infection
On day 21 after revaccination the mice from all groups were inoculated intranasally with 300
MID50 of A/Shanghai/2/2013(H7N9) CDC-RG influenza virus and intraperinoneally injected
with 325 CFU of S. pneumoniae 19F serotype 24 hours apart. Isolation of infectious strepto-
cocci from spleen was carried out on 48 hours after bacterial infection as stated above.
Simultaneously with secondary bacterial infection, half of the mice vaccinated using GBSV
or LAIV+GBSV were injected intraperitoneally with a mixture of histamine receptor blockers
H1 type (chloropyramine, “Egis”, Hungary) and H2 (famotidine, “Gedeon Richter”, Hungary),
each at 6.7 mg / kg of weight, in a volume of 0.1 ml.
Statistics
Data was processed using Statistica software, version 6.0 (StatSoft, Inc. Tulsa, Oklahoma,
USA). Means and standard errors of means (SEM) were calculated to represent virus titers.
Reciprocal antibody titers were expressed as log 2 (HI) or as log 10 (ELISA) and presented as
mean±SEM. To compare two independent groups we used a Mann-Whitney U-test. To com-
pare multiple independent groups we used a Kruskal-Wallis ANOVA test. The p-value <0.05
were considered to be statistically significant.
Results
Immunogenicity
Nasal immunization of DBA/2 mice using either A/H7N3 LAIV or combinations of the LAIV
with two GBS polypeptides led to conversions of serum HI antibody conversions against the
A/17/Mallard/Netherlands/00/95 (H7N3) strain (Fig 1A).
The introduction of two-doses of LAIV or associated LAIV+GBSV vaccine was required to
achieve HI antibody response. The titers of HI antibody against heterologous A/Shanghai/2/
2013(H7N9) CDC-RG virus were even higher than that of the homologous virus. At the same
time, local IgA response was more pronounced against homologous A/17/Mallard/Nether-
lands/00/95 (H7N3) than against A/Shanghai/2/2013(H7N9) CDC-RG (Fig 1C). We detected
serum IgG in equal titers against either whole A/17/Mallard/Netherlands/00/95 (H7N3) or A/
Associated vaccine against post-influenza pneumococcal infections
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Shanghai/2/2013(H7N9) CDC-RG influenza viruses (Fig 1B). Unexpectedly, the sera of LAIV-
immunized mice reacted with different serotypes of pneumococci. As seen in Fig 1D sera, pos-
itive for the A/17/Mallard/Netherlands/00/95 (H7N3) virus cross-reacted with various pneu-
mococcal serotypes according to the results of dot-blot analysis. In the sera of control mice, no
such response was detected (Fig 1D). Since this experiment we used a pool of sera, the signifi-
cance of differences was not established.
Serum IgG, specific to GBS polypeptides P6 and ScaAB was detected on day 21 and 42 post
primary immunization in titers significantly higher compared to controls (Fig 2A).
Intranasal immunization using GBSV or LAIV+GBSV raised IgG not only against GBS
components P6 and ScaAB (Fig 2A), but also against S. pneumoniae immobilized on the wells
Fig 1. Immune response on day 21 and day 42 after intranasal immunization using LAIV or LAIV+GBSV (8 mice
in each group, including PBS group). (A) serum HI antibodies against A/17/Mallard/Netherlands/00/95 (H7N3) and
A/Shanghai/2/2013(H7N9) CDC-RG influenza viruses, �—P<0.005 compared to day 21. (B) serum virus-specific IgG,
�—P<0.005 compared to day 21. (C) local virus-specific IgA, �—P<0.05. (D) dot-blotting analysis of pool sera
obtained after LAIV-only immunization, reacting with S. pneumoniae strains.
https://doi.org/10.1371/journal.pone.0218544.g001
Fig 2. Immune response against GBS components or S. pneumoniae 19F serotype after intranasal immunization
using GBSV or LAIV+GBSV. (A) serum IgG specific to GBS recombinant peptides P6 and ScaAB on day 42 after first
vaccination (ELISA); �—P< 0.01, ��—P< 0.001 compared to PBS group. (B) plot of serial serum dilution reacting
with precipitated S. pneumoniae serotype 19F (ELISA); each curve represents data from six tested sera; the arrow
represents the control level obtained as mean OD450 of 5–8 negative wells plus 3 SD.
https://doi.org/10.1371/journal.pone.0218544.g002
Associated vaccine against post-influenza pneumococcal infections
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surface of plates for immunological reactions (Fig 2B). In this case, the reaction of ScaAB-posi-
tive sera was more pronounced compared to reaction of P6-positive with S. pneumoniae of
serotype 19F (Fig 2B).
Isolation of infectious virus and streptococci from the lungs and weight
loss after viral-bacterial challenge
After intranasal post-influenza pneumococcal infection, the infectious virus A/Shanghai/2/
2013 (H7N9) CDC-RG was not isolated from the lungs of mice immunized using LAIV, and
this may result in a 100-fold reduction of secondary bacterial infections (Fig 3A).
The associated virus-bacterial vaccine prevented not only viral infection of the lungs, but
also reduced pneumococcal titers by 25,000x (Fig 3A). Thus, mixed vaccination was most
effective in reducing bacterial lung titers during secondary bacterial infection.
Combined virus-bacterial infection led to increased lung titers of both infectious virus and
infectious pneumococcus in the lungs. As can be seen in Fig 3B, both viral and bacterial load
in mock-vaccinated mice after mixed infections was higher compared with mono-infections,
although these differences were not statistically significant.
Although mono- infection with A/Shanghai/2/2013(H7N9) CDC-RG influenza virus was
not lethal for mice, 70% of mock-vaccinated animals died after super-infection with a non-
lethal dose of bacteria (Fig 3C). Under conditions of super-infection, LAIV did not protect
against mortality compared to super-infected PBS controls. However, unlike intact mice, the
surviving mice in this group did not lose weight (Fig 3D). These data, together with decreased
bacterial lung titers, allow us to conclude that LAIV created a partial defense against post-
Fig 3. The A/Shanghai/2/2013(H7N9) CDC-RG influenza virus and S. pneumoniae serotype 3 isolation from the
lungs. (A) Influenza virus and S. pneumoniae titers in the lungs with mixed virus-bacterial infection at 72 hours after
primary viral infection (n = 6–8); �—P< 0.01, ��—P< 0.001 compared to mock-vaccinated animals. (B) Influenza
virus and S. pneumoniae titers in the lungs of mock-vaccinated animals at 72 hours after A/H7N9 mono-infection or
after 48 hours after S. pneumoniae serotype 3 mono-infection (n = 6). () lethality after mixed influenza and
pneumococcal infections (n = 10)/ (D)–body weight dynamics after mixed influenza and pneumococcal infections
(n = 10).
https://doi.org/10.1371/journal.pone.0218544.g003
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influenza pneumococcal infection. Vaccines containing recombinant peptides of GBS pro-
vided the best protection from mortality after pneumococcal super-infection with 70% of the
mice surviving in the case of LAIV+GBSV immunization, and 60% surviving in GBSV vaccine
group (Fig 3C).
Pathomorhological data
Data on the isolation of infectious virus and pneumococci from the lungs were confirmed by
histological examination of hematoxylin-eosin stained lung sections. The evaluation of patho-
morphological signs of post-influenza pneumococcal infection involved a comparison with a
mono-infection with the A/Shanghai/2/2013(H7N9) CDC-RG influenza virus or pneumococ-
cal infection. In non-treated mice, lung tissue structure was normal (Fig 4A) with the excep-
tion of acute non-specific microcirculation disorders.
These changes comprised clusters of a small amount of red blood cells in the lumen of part
of the alveoli in the sub-pleural regions and acute plethora (Fig 4I). The epithelial lining of the
major bronchi was preserved, the epithelium was single-row, of normal structure, and there
were no contents in the lumen or cell infiltration of the bronchial walls (Fig 4E). Acute exuda-
tive bronchitis developed at 72 hours after viral mono-infection, with accumulations of a small
amount red blood cells in part of alveoli lumen (Fig 4B, arrowhead), acute plethora and mar-
ginal leukocyte was standing in the lumen of blood vessels (Fig 4J, arrowhead). In the lumen of
the large bronchi leukocyte exudate (Fig 4F), the integrity of the mucous membrane was pre-
served over a large extent, in some areas with focal leukocyte infiltration of the epithelial layer
(arrowhead).
Focal bacterial bronchopneumonia developed after pneumococcal mono-infection (Fig 4C,
4G and 4K). Disintegrating polymorphonuclear leukocytes were detected in pneumonic foci,
when lymphocytes were observed among desquamated cells of the alveolar epithelium (Fig 4C,
Fig 4. Hematoxylin-eosin stained sections from lung tissues of mice at 3 days after A/Shanghai/2/2013(H7N9)
CDC-RG infection and at 48 hours after S. pneumoniae infection or at 48 hours after serial viral-bacterial
infections. (A,B,C,D,F,K,L) Magnification, ×400. (E,G,H,I,J) Magnification, ×200. The meanings of the arrows are
indicated in the text.
https://doi.org/10.1371/journal.pone.0218544.g004
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arrowhead). In the lumen of a part of the large bronchi single polymorphonuclear leukocytes
were detected, the epithelium was damaged, with the formation of multi-row, peribronchial
polymorphoncellular infiltration followed by a significant admixture of polymorphonuclear
leukocytes (Fig 4G, arrowhead).
When pneumococci were administered intranasally at 24 hours after the viral infection, the
signs of macrofocal bacterial pleuropneumonia were registered on day 2 after bacterial infec-
tion (Fig 4D, 4H and 4L). Therefore, co-infection greatly increased the severity of the morpho-
logical changes in the lungs.
Sequential viral-pneumococcal intranasal infection in LAIV-immunized mice caused focal
serous-desquamative pneumonia (Fig 5A) with small areas of serous pneumonia, desquamated
cells of the alveolar epithelium, single polymorphonuclear leukocytes, lymphocytes and eryth-
rocytes found in the lung tissue.
There were no contents in the lumen of the large bronchi; the bronchus wall was of normal
structure (Fig 5D).
After GBSV immunization, sequential viral-bacterial challenge lead to large focal, partly
confluent destructive pleuropneumonia, when the formation of small foci of purulent destruc-
tion was observed (Fig 5B, arrowhead) along with focal leukocyte infiltration of the medium
bronchi mucous membrane (Fig 5E, arrowhead) and severe damage to the vascular endothe-
lium (Fig 5H, arrowhead). That is, the changes were characteristic of a virus-bacterial
infection.
After associated LAIV+GBSV vaccination, focal serous and hemorrhagic pneumonia pre-
vailed in conditions of post-influenza bacterial super-infection (Fig 5C, arrowhead). In this
case, the walls of the major bronchi retained their usual structure (Fig 5F), although wide-
spread perivascular polymorphocellular infiltration and pronounced damage to the vascular
endothelium were noted (Fig 5I, arrowhead). Thus, bacterial super-infection complicated the
morphological pattern of lung lesions compared with viral or bacterial mono-infection, despite
Fig 5. Comparative study of pathological changes in the lungs of mice at 48 hours after serial A/Shanghai/2/2013
(H7N9) CDC-RG and S. pneumoniae infections. (A) Magnification, ×100; B,C,E,Y– 400. (D,F,G,I)Magnification,
×200. The meanings of the arrows are indicated in the text.
https://doi.org/10.1371/journal.pone.0218544.g005
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the fact that there was no significant increase in viral and bacterial reproduction. After immu-
nization with LAIV or mixed viral-bacterial immunization, lung damage was limited to hem-
orrhagic and serous changes, while immunization with GBS did not prevent viral-bacterial
damage to the lungs, as was established by intranasal post-influenza pneumococcal super-
infection. We also attempted to study how the associated virus-bacterial immunization will act
against the generalized post-influenza pneumococcal infection.
Systemic post-influenza pneumococcal infection of immunized mice
S. pneumoniae were administered intraperitoneally to reproduce systemic post-influenza
pneumococcal infection in mice. Unlike intranasal pneumococcal superinfection, after sys-
temic S. pneumoniae super-infection we observed increased mortality at 48 hours among mice
that received GBSV or LAIV+GBSV (Fig 6A).
In GBSV or LAIV+GBSV groups, there was an increased isolation of pneumococci from
the spleens (Fig 6B). The introduction of histamine blockers significantly reduced the infecting
pneumococci isolation from the spleen of mice (Fig 6B). Parenteral administration of antihis-
tamines also reduced the release of infectious virus from the lungs in the group of mice immu-
nized with streptococcal peptides (Fig 6D). These data allow us to conclude that a decrease in
infection of internal organs after introduction of chloropyramine and famotidine can be
caused by the abolition of the impact of histamine on the vascular hiperpermeability and inhi-
bition of the development of sepsis.
Discussion
Live attenuated influenza vaccines are of particular importance for the prevention of pandemic
and potentially pandemic influenza due to formation of systemic and strong local (secretory)
Fig 6. Intranasal challenge of immunized mice with A/Shanghai/2/2013(H7N9) CDC-RG followed by parenteral
super-infection 24 hours apart with S. pneumoniae serotype 19F. (A) Lethality at 24 hours after parenteral post-
influenza infection with different doses of pneumococci in groups of immunized mice (n = 8). (B) Bacterial load in the
spleens 48 hours after post-influenza parenteral pneumococcal infection with 325 CFU (n = 5). (C) Decreased bacterial
load in the spleens after antihistamines (AH) administration (n = 5). �- P = 0.036 compared to pneumococcal titers
with no AH administration. (D) Infectious virus isolation from the lungs (“AH” means antihistamine administration)
24 hours after post-influenza parenteral pneumococcal infection (n = 5); �—P = 0.009.
https://doi.org/10.1371/journal.pone.0218544.g006
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immunity. Intranasal vaccine implementation produces immune response similar to natural
infection, and therefore induces an early, broad and long–lasting protection [15]. The cost of
live vaccine is several times lower compared to inactivated vaccines, and the capacity of the
LAIV biotechnological production process is significantly higher [15].
Peptide vaccines based on superficial factors of bacteria (highly conservative lipoprotein
virulence factors, enzymes such as nucleases, proteases, hemolysin, peptidase) are preferable
over polysaccharide vaccines due to the smaller degree of variability and higher immunogenic-
ity. That is why we decided to study immunogenicity and protection against pneumococcal
infection of ScaAB, which is the major surface lipoprotein of GBS closely related to PsaA pro-
tein of S. pneumoniae [16]. PsaA protein is considered to be the most promising vaccine candi-
date against S. pneumoniae infection [17]. Recently, Seon et al., 2017 have shown that
attenuated pneumococcus pep27 mutant which protect mice against secondary pneumococcal
challenge after influenza virus infection increased antibody titers against PspA protein but not
type 2 capsular polysaccharide These data suggest that although pneumococcus is surrounded
by a powerful polysaccharide capsule, at the stages of its reproduction, the internal proteins
become available for molecular interaction and the antibodies forming against these proteins
are protective [18].
When mice were immunized with LAIV or LAIV in combination with GBSV, the immune
response of anti-hemagglutinating antibodies was observed not only to the homologous A/
H7N3 virus, but also to the heterologous A/H7N9. Data of HI analysis confirm previously
obtained data on outbred mice about a higher immune response of HI antibodies against A/
H7N9 viruses after immunization with A/H7N3 vaccine [19].
We showed that the sera of mice, positive for the influenza virus, reacted with pneumococci
of various serotypes, including 3 and 19F, which were later used for intranasal and parenteral
infection, respectively. This phenomenon presumably can be explained by receptor interac-
tions, as previously it has been demonstrated in vitro that HA of influenza viruses A/H1N1
and A/H3N2 recognizes the α2,6-linked sialic acid present in the capsular polysaccharide of
Streptococcus suis [20].
Data on the formation of serum IgG against streptococcal polypeptides confirm the evi-
dence that polypeptides cause a pronounced systemic immune response when administered
intranasally. The data obtained on the model of systemic pneumococcal post-influenza infec-
tion serve as an additional confirmation of the high immunogenicity of streptococcal peptides
after intranasal administration. In this case, the mortality of mice was higher in those groups
that were immunized using streptococcal peptides and had serum IgG against ScaAB, which is
similar to PsaA protein of S. pneumoniae. This was confirmed in ELISA-test when ScaAB-posi-
tive sera reacted with S. pneumonia 19F serotype rather than P6-positive sera (Fig 2B).
Previously, it was shown that live attenuated influenza vaccines may significantly reduce
bacterial disease during influenza epidemics [21]. In our study, the introduction of LAIV had a
positive effect on the course of a virus-bacterial infection, when viral replication and bacterial
infection in the lungs after challenge was lower compared to non-vaccinated animals (Fig 3B).
It is noteworthy, that the decrease in bacterial lung infection after LAIV vaccination was even
more pronounced than after the administration of GBSV alone. Of all vaccine preparations,
only the associated vaccination using LAIV+GBSV resulted in the most significant reduction
in lung bacterial infection. It can be assumed, that this effect may be associated not only with
the formation of antibodies, but also with a decrease in primary influenza infection.
The results of quantitative viral and bacteriological studies corresponded to the morpholog-
ical features in the lungs which suggest that immunization with LAIV+GBSV was the most
successful in reducing the severity of pneumococcal post-influenza super-infection. It is note-
worthy that GBSV alone did not prevent the virus-bacterial pulmonary lesions and body
Associated vaccine against post-influenza pneumococcal infections
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weight decrease, although at the same time GBSV protected against mortality an additional
30% of mice. This presumably can be explained by the presence of the ScaAB peptide in the
preparation.
The mechanisms of partial protective effect against streptococcal infection after LAIV vacci-
nation may be associated with the processes of bacterial adherence. One of possible reasons for
changing the sensitivity of tissues to bacterial load associated with viral reproduction is that
the virus can change peptide profile of the cell membrane and form unusual for intact cell
receptor sites. The receptor sites for bacteria may be formed on the cell membrane by displac-
ing host proteins by viral polypeptides. So, it was previously shown that the transfer of HA-
specific CD8 T cell clones in transgenic mice with expressed HA antigen on the alveolar epi-
thelial cells leads to progressive lethal lung injury in the absence of active viral reproduction
[22]. The second most important antigenic component of the influenza virus, neuraminidase,
as a part of an influenza virus may nonspecifically bare receptor located in the membrane of
epithelial cells [23].
When simulating intranasal bacterial super-infection, the associated virus-bacterial immu-
nization protected better than mono-LAIV or GBSV. However, when infected with pneumo-
cocci, the development of systemic spread cannot be ruled out [24], especially against the
background of primary influenza infection. In this regard, we reproduced secondary systemic
pneumococcal infection in mice immunized with various preparations through peritoneal
infection. It was unexpectedly found that increased levels of IgG antibodies to GBS peptides in
groups of mice immunized with GBSV were associated with the development of severe sys-
temic infection. The problems of antibody-dependent enhancement (ADE) are widely dis-
cussed in scientific literature, including discussions on vaccine development issues. ADE
syndrome is characteristic of dengue fever, in which it initially attracted attention and was first
described [25], but also is observed in other infections [26, 27]. One of the factors contributing
to ADE development is considered to be the "noncanonical" mechanism of antigen presenta-
tion, due to the involvement in the presentation process of many cells expressing Fcγ receptors
(CD16, CD32, CD64) and activated by IgG-containing immune complexes, in particular B-
cells [28].
In conclusion, it should be said that using a mouse model, we demonstrated that bacterial
pneumococcal infection seriously complicates the course of A/H7N9 influenza infection. Evi-
dence has been obtained that associated immunization with the use of LAIV and recombinant
peptides of GBS is capable to prevent post-influenza pneumonia. Data on the positive effect of
LAIV on the course of post-influenza pneumococcal pneumonia are especially important in
light of the fact that LAIV is widely used in a number of countries for the vaccination of chil-
dren [29]. At the same time, generalized infection of immune mice was more severe in the
groups immunized using recombinant GBS peptides which can be explained by antibody-
dependent enhancement. In this case, the introduction of histamine receptors blockers of type
1 and 2 reduced the burden of secondary pneumococcal infection -.
In mice with high titers of IgG antibodies against GBS peptides, we observed a high pneu-
mococcal colonization of organs and an increase in lethality on 48 hours, i.e. signs of bacter-
emia and septic shock. We assume this can be attributed to activation of mast cell by IgG-
containing immune complexes. After parenteral infection, the bacteria immediately met with
a large excess of circulating antibodies. In this case, the must cells activation should followed
by a massive release of histamine. This caused a systemic vascular hyperpermeability with the
vascular leak and expansion of bacterial colonization of organs. These processes could be
aggravated by developing influenza infection.
Antihistamines in our experiments interrupted the development of sepsis by blocking the
vascular hyperpermeability after histamine release [30]. These data indicate that during the
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reinfection of immune persons, the immunocomplex pathway of mast cell activation by IgG-
containing immune complexes should be taken into account and carefully studied. In particu-
lar, the dependence of the phenomenon of increasing bacterial contamination of internal
organs and increasing mortality on the dynamics of IgG antibodies (the timing of their appear-
ance, the rate of increase in concentration, isotypic composition) should be studied in experi-
mental models. Anyway, the ADE-phenomenon should be studied when immunizing not only
against dengue or Zika viruses [31, 32], but also in influenza and pneumococcal immunization.
We consider our data as a contribution to this topic.
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